AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation...
ABCL635 demonstrated a favorable tolerability profile, with no observed liver toxicity, and achieved potent and sustained reductions in biomarkers of target engagement. ...
Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...
Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...
Barchart Research What to Expect from ABCL Earnings ABCL Generated May 8, 2026 Current Price $5.24 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.73% AbCellera's ABCL635 Phase One Data...
AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026...
AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic...
AbCellera (Nasdaq: ABCL) will announce its first quarter 2026 financial results on Monday, May 11, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)...
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. ...
SoftBank revealed new positions in each of these three companies.